NEW YORK--(BUSINESS WIRE)--Ophthotech Corporation (Nasdaq:OPHT) today announced financial results for the third quarter ended September 30, 2015 and provided an update on the Company’s business and product development programs.
“We have achieved many significant milestones that have us on track to reach our goal to provide initial, topline data from both Phase 3 trials of Fovista® in combination with Lucentis in the fourth quarter of 2016,” said David R. Guyer, M.D., Chief Executive Officer and Chairman of the Board of Ophthotech.
Help employers find you! Check out all the jobs and post your resume.
